Blarcamesine
- Generic Name
- Blarcamesine
- Drug Type
- Small Molecule
- Chemical Formula
- C19H23NO
- CAS Number
- 195615-83-9
- Unique Ingredient Identifier
- 9T210MMZ3F
- Indication
Investigated for use/treatment in breast cancer.
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 132
- Registration Number
- NCT04575259
- Locations
- 🇪🇸
Hospital del Henares, Coslada, Spain
🇪🇸Hospital ClÃnico San Carlos, Madrid, Spain
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 300
- Registration Number
- NCT04314934
- Locations
- 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇩🇪Charite University Medicine, Berlin, Germany
🇦🇺Gold Coast Memory Disorders Clinic, Southport, Quennsland, Australia
ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome
- Conditions
- Rett Syndrome
- Interventions
- Drug: Placebo oral liquid
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 92
- Registration Number
- NCT04304482
- Locations
- 🇬🇧
King's College of London, London, United Kingdom
🇦🇺Queensland Children's Hospital, Brisbane, Queensland, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
ANAVEX2-73 Study in Patients With Rett Syndrome
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT03941444
- Locations
- 🇬🇧
Manchester CGM, St. Mary's Hospital, Manchester, UK, United Kingdom
🇦🇺HammondCare, Greenwich, New South Wales, Australia
🇬🇧King's College of London, London, UK, United Kingdom
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 509
- Registration Number
- NCT03790709
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇦🇺The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH), Adelaide, South Australia, Australia
🇨🇦Toronto Memory Program, Toronto, Ontario, Canada
ANAVEX2-73 Study in Parkinson's Disease Dementia
- Conditions
- Parkinsons Disease With Dementia
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 132
- Registration Number
- NCT03774459
- Locations
- 🇦🇺
KaRa MINDS, Macquarie Park, Australia
🇪🇸Hospital Santa Caterina, Girona, Spain
🇪🇸Clinica Ruber Internacional, Madrid, Spain
Study of ANAVEX2-73 in Patients With Rett Syndrome
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 31
- Registration Number
- NCT03758924
- Locations
- 🇺🇸
UAB | The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 21
- Registration Number
- NCT02756858
- Locations
- 🇦🇺
Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia
🇦🇺Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 32
- Registration Number
- NCT02244541
- Locations
- 🇦🇺
Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Caulfield Hospital, Melbourne, Victoria, Australia
🇦🇺Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.